tmpyp4 (catalog no. [cat Search Results


tmpyp4  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology tmpyp4
A Each cell was transfected with siTERT. Cell viability was measured after 144 h of siTERT treatment using CCK-8. B The knockdown efficiency of TERT. mRNA was collected after 72 h of siTERT treatment. C The IC 50 of the TERT inhibitors (BIBR1532, trichostatin, doxorubicin, <t>TMPyP4,</t> suramin, and VX222) in MeT-5A (WT, LATS1 KO, and LATS2 KO). The diluted TERT inhibitor was applied to each cell, and cell viability was measured after 144 h of incubation using CCK-8. D hTERT D712A- and hTERT T249A-overexpressing plasmids were transfected into HOMC-D4 (non-target [shNT] and LATS1/2 KD) and MeT-5A (WT and LATS2 KO) cells. The cell viability was measured after 144 h of transfection using CCK-8. All experiments were performed at least three independent times. Data are presented as means ± SD, and p values were calculated using the Tukey-Kramer method. * indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001. n.s. - no significant difference.
Tmpyp4, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tmpyp4/product/Santa Cruz Biotechnology
Average 93 stars, based on 1 article reviews
tmpyp4 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


A Each cell was transfected with siTERT. Cell viability was measured after 144 h of siTERT treatment using CCK-8. B The knockdown efficiency of TERT. mRNA was collected after 72 h of siTERT treatment. C The IC 50 of the TERT inhibitors (BIBR1532, trichostatin, doxorubicin, TMPyP4, suramin, and VX222) in MeT-5A (WT, LATS1 KO, and LATS2 KO). The diluted TERT inhibitor was applied to each cell, and cell viability was measured after 144 h of incubation using CCK-8. D hTERT D712A- and hTERT T249A-overexpressing plasmids were transfected into HOMC-D4 (non-target [shNT] and LATS1/2 KD) and MeT-5A (WT and LATS2 KO) cells. The cell viability was measured after 144 h of transfection using CCK-8. All experiments were performed at least three independent times. Data are presented as means ± SD, and p values were calculated using the Tukey-Kramer method. * indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001. n.s. - no significant difference.

Journal: Cell Death Discovery

Article Title: SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated malignant mesothelioma

doi: 10.1038/s41420-022-01232-w

Figure Lengend Snippet: A Each cell was transfected with siTERT. Cell viability was measured after 144 h of siTERT treatment using CCK-8. B The knockdown efficiency of TERT. mRNA was collected after 72 h of siTERT treatment. C The IC 50 of the TERT inhibitors (BIBR1532, trichostatin, doxorubicin, TMPyP4, suramin, and VX222) in MeT-5A (WT, LATS1 KO, and LATS2 KO). The diluted TERT inhibitor was applied to each cell, and cell viability was measured after 144 h of incubation using CCK-8. D hTERT D712A- and hTERT T249A-overexpressing plasmids were transfected into HOMC-D4 (non-target [shNT] and LATS1/2 KD) and MeT-5A (WT and LATS2 KO) cells. The cell viability was measured after 144 h of transfection using CCK-8. All experiments were performed at least three independent times. Data are presented as means ± SD, and p values were calculated using the Tukey-Kramer method. * indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001. n.s. - no significant difference.

Article Snippet: Inhibitor reagents targeting hTERT (BIBR1532; Cat No. SC-20843) [ ], trichostatin (Cat No. SC-3511) [ ], doxorubicin (Cat No. SC-200923) [ ], TMPyP4 (Cat No. SC-204346), and suramin (Cat No. SC-200833) were purchased from Santa Cruz Biotechnology (California, USA).

Techniques: Transfection, CCK-8 Assay, Knockdown, Incubation